Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Dengue
Pertussis
SAGE documentation
GRADE table
Clear all
Type of publications
SAGE documentation
(9)
Topics
GRADE table
(9)
Regions
Countries
Diseases
COVID-19
(2)
Dengue
(5)
Pertussis
(2)
Cholera
(1)
Diphtheria
(1)
Haemophilus influenzae type B
(3)
Hepatitis A
(6)
Influenza
(11)
Measles
(6)
Meningococcal disease
(4)
Rubella
(1)
Typhoid
(2)
Publication date
2022
(2)
2018
(5)
2015
(2)
Target population
Available to download in languages
English (EN)
(9)
9 results found
2022
∙
SAGE
Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19
2022
∙
SAGE
Annexes to the interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19
2018
∙
SAGE
What is the duration of protection/risk in seronegative individuals 9-16 years of age vaccinated with CYD-TDV?
2018
∙
SAGE
What is the duration of protection/risk in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
What is the risk of other serious adverse events (non-dengue) in seropositive individuals 9-16 years of age vaccinated with CYD-TDV?
2015
∙
SAGE
Safety of pertussis vaccines in immunocompetent infants and children
2015
∙
SAGE
Protective Efficacy/Effectiveness of Whole Cell Pertussis Vaccines (wP) in Immunocompetent Infants and Children
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register